Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Novel Therapy for the Treatment of Chest Wall Progression of Breast Cancer

This study has been completed.
Sponsor:
Collaborators:
Tufts Medical Center
Information provided by:
Rogers Sciences Inc.
ClinicalTrials.gov Identifier:
NCT01262716
First received: December 15, 2010
Last updated: October 24, 2011
Last verified: October 2011

December 15, 2010
October 24, 2011
December 2010
August 2011   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01262716 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Novel Therapy for the Treatment of Chest Wall Progression of Breast Cancer
A Novel Therapy for the Treatment of Chest Wall Progression of Breast Cancer

This study will assess safety and ergonomics/engineering design of a novel cancer treatment, Continuous Low Irradiance Photodynamic therapy (CLIPT). We will assess the effects on primary and metastatic tumors involving the skin, in particular to improve the functionality, efficiency and wearability of the light delivery device (LDD) as well as the overall treatment in subjects with chest wall recurrences of breast cancer. An ongoing study (IRB# 8227), sponsored by a Susan G. Komen Breast Cancer Foundation grant, using a 1st generation LDD device has evaluated and determined a dose-limiting toxicity of CLIPT for subjects with chest wall recurrences of breast cancer.

A Diomed laser will be the device used in this study. The Diomed laser will deliver 630 nm (red spectrum) light through a Fiber Optic Patch. The Fiber Optic patch will be compatible with the laser, delivering light to a designated region on the patient's skin.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

The study population will consist of 3 female patients. Eligible patients will be recruited from cancer centers in North America specializing in breast cancer. Recruitment has begun with the Hematology/Oncology, Dermatologic Oncology, and Radiation Oncology programs at Tufts Medical Center, Rhode Island Hospital and the teaching hospitals affiliated with Tufts and Brown Universities. All research related activity will only take place at the Tufts Medical Center.

Breast Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
3
August 2011
August 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients > 18 years of age, with primary or metastatic cutaneous tumors that may or may not have been previously irradiated.
  • ECOG performance status < 3.
  • Patients must not have received any systemic anti-cancer therapy within 30 days prior to enrolling in this study.
  • Patients must not have received radiation therapy to the target site within 60 days of enrolling on this study.
  • Skin of target site and control site must be grade 0 or 1 by Common Terminology
  • Patients must have a target lesion and normal peri-umbilical skin that can be covered by the fiber-optic mesh used to deliver CLIPT (10 x 10 cm, or 3 x 3).
  • If located on an extremity, the target lesion must not cover more than 50% of the diameter of the extremity at the level at which it is located.
  • Absolute neutrophil count > 1000.
  • Adequate coagulation status as indicated by platelet count > 50,000, PT and PTT < 1.5 time the upper limit of normal.
  • Patients must sign informed consent.

Exclusion Criteria:

  • Male patients not considered for this study.
  • Patients must have a target lesion in a location other than the hands, feet, genitals, or face. Lesions in those locations will be excluded.
  • Patients with medical conditions associated with photosensitivity, such as cutaneous porphyria or a collagen vascular disease, or with known allergies to porphyrins will be excluded.
  • Pregnant and nursing patients will be excluded. Women of child-bearing potential must have a negative serum or urine pregnancy test prior to enrollment.
  • Patients taking medications known to cause photosensitivity (tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics, griseofulvin, and fluoroquinolones, St. John's wort and amiodarone) will be excluded.
  • Patients with severe hepatic dysfunction (total bilirubin, AST, or ALT > five times upper limit of normal) will be excluded.
Female
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01262716
9439, R43CA139644-01A1
Yes
Samuel L Hill, Rogers Sciences Inc.
Rogers Sciences Inc.
  • National Institutes of Health (NIH)
  • National Cancer Institute (NCI)
  • Tufts Medical Center
Study Director: Gary S. Rogers, M.D. Rogers Sciences Inc.
Principal Investigator: Roger A. Graham, M.D. Tufts Medical Center
Rogers Sciences Inc.
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP